General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

  • Raffaele De Caterina, Institute of Cardiology, G. d'Annunzio University-- Chieti, Ospedale SS. Annunziata, Via dei Vestini, 66013 Chieti, Italy.
  • ,
  • Steen Husted, Danmark
  • Lars Wallentin
  • ,
  • Felicita Andreotti
  • ,
  • Harald Arnesen
  • ,
  • Fedor Bachmann
  • ,
  • Colin Baigent
  • ,
  • Kurt Huber
  • ,
  • Jørgen Jespersen
  • Steen Dalby Kristensen
  • Gregory Y.H. Lip, Danmark
  • João Morais
  • ,
  • Lars Hvilsted Rasmussen, Danmark
  • Agneta Siegbahn
  • ,
  • Freek W A Verheugt
  • ,
  • Jeffrey I Weitz
  • ,
  • European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease
Contrary to previous models based on plasma, coagulation processes are currently believed to be mostly cell surface-based, including three overlapping phases: initiation, when tissue factor-expressing cells and microparticles are exposed to plasma; amplification, whereby small amounts of thrombin induce platelet activation and aggregation, and promote activation of factors (F)V, FVIII and FXI on platelet surfaces; and propagation, in which the Xase (tenase) and prothrombinase complexes are formed, producing a burst of thrombin and the cleavage of fibrinogen to fibrin. Thrombin exerts a number of additional biological actions, including platelet activation, amplification and self-inhibition of coagulation, clot stabilisation and anti-fibrinolysis, in processes occurring in the proximity of vessel injury, tightly regulated by a series of inhibitory mechanisms. "Classical" anticoagulants, including heparin and vitamin K antagonists, typically target multiple coagulation steps. A number of new anticoagulants, already developed or under development, target specific steps in the process, inhibiting a single coagulation factor or mimicking natural coagulation inhibitors.
TidsskriftThrombosis and Haemostasis
Sider (fra-til)569-79
Antal sider11
StatusUdgivet - apr. 2013

Se relationer på Aarhus Universitet Citationsformater

ID: 68790962